Published in Vaccine Weekly, May 3rd, 2006
"I am delighted to report that our achievements during the past year have brought us closer to our goal of commercializing human therapeutics based on our small molecule 'molecular chaperone' co-induction technology," said CytRx president and CEO Steven A. Kriegsman. "Most notable among our achievements in 2005 was the advancement of our orally-available small molecule drug candidate arimoclomol into Phase II development for the treatment of amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease.
"We also made excellent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly